Plain-English translation of NCT04857502 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This early-stage trial is testing a new imaging agent called 99mTc-PSMA-I&S that helps doctors visualize prostate cancer in the body. The medication is given by injection, and special scans are used to see where it concentrates. Researchers want to understand how this treatment works in real patients and whether it can help surgeons find and remove cancer more effectively.
Doctors need better ways to locate prostate cancer before surgery, especially when the disease has spread to lymph nodes or come back after initial treatment. This medication may help surgeons see exactly where cancer is hiding so they can remove it more completely.
You likely qualify if…
You likely don't qualify if…
The first five participants will receive an injection of the medication and then return for five imaging scans over about 6 days to map where the medication goes in your body. All participants then receive a second injection before their standard prostate cancer surgery. The scans and injections are the main additions to your regular surgical care—your surgery itself remains unchanged.
AI-generated summary from trial data · Aug 13, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
Jonsson Comprehensive Cancer Center
Enrollment target
~30 participants
Started
April 2021
Primary completion
June 2027
Sex
Male only
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Deepu Varughese
UCLA / Jonsson Comprehensive Cancer Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.